The Transactional Landscape Of ADCs: The Powerhouse of Antibody Drug Conjugates

Back Bay Life Science Report

Контент предоставлен Back Bay Life Science Advisors, Jonathan P. Gertler, and Peter Bak. Весь контент подкастов, включая эпизоды, графику и описания подкастов, загружается и предоставляется непосредственно компанией Back Bay Life Science Advisors, Jonathan P. Gertler, and Peter Bak или ее партнером по платформе подкастов. Если вы считаете, что кто-то использует вашу работу, защищенную авторским правом, без вашего разрешения, вы можете выполнить процедуру, описанную здесь https://ru.player.fm/legal.

1y ago 25:54

MP3•Главная эпизода

In this episode, Dr. Peter Bak is joined by Trent Gordon and Dr. Mavra Nasir as they discuss their Bioprocess Online article published earlier this year, “The Transactional Landscape of ADCs: A Payday for Payloads.” This conversation explores the dynamics and data within the emerging ADC field, including:

Background information on the class of therapeutics known as ADCs, which have been on the market since 2000
The number of headlines around ADCs lately, especially the standing ovation the data from Enhertu received at ASCO in 2022, making waves in breast cancer treatment
Deal structures and the BD side of ADCs, and their extended revenue generation potential
Where the field is headed, in terms of clinical, BD and commercial standpoints

Read and connect with our authors: The Transactional Landscape Of ADCs: A Payday for Payloads

29 эпизодов

#Fitness #Medicine #Bay Life Science Advisors #Jonathan P. Gertler #Biopharma #Investmentbanking #LifeSciences #Medtech